通过布鲁萨托尔向FOXM1/PSAT1轴,可以抑制肺癌恶性进展
Siyi Ou1, Xiaobo Wang2, Yulan Sun2
1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China; Department of Respiratory and Critical Care Medicine, the First People's Hospital of Qinzhou, Qinzhou, Guangxi 535000, China.
布鲁萨托尔是一种来自Brucea javanica的化合物,通过降低索胺转移酶1 (PSAT1) 的调节来抑制肺癌. FOXM1/PSAT1通路是布鲁萨托尔的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 布鲁萨托尔 (BRU),来自Brucea javanica,表现出抗癌性质.
- 布鲁萨托尔在肺癌中的确切作用机制尚不完全理解.
- 确定下游目标对于了解布鲁萨托尔的治疗潜力至关重要.
研究的目的:
- 阐明布鲁萨托尔在肺癌中的下游目标和机制.
- 调查素氨基转移酶1 (PSAT1) 在布鲁萨托尔抗癌作用中的作用.
- 探索转录因子FOXM1在调节PSAT1.1中的参与.
主要方法:
- 定量实时PCR和西式斑点测试,以评估mRNA和蛋白质水平.
- 在体外和体内实验中评估PSAT1过度表达对布鲁萨托尔疗效的影响.
- 染色体免疫沉测试以确定FOXM1与PSAT1促进体的结合.
主要成果:
- 布鲁萨托尔显著降低了PSAT1.1的mRNA和蛋白质表达.
- 过度表达PSAT1可以抵消布鲁萨托尔在肺癌细胞中的抗瘤作用.
- FOXM1直接与PSAT1促进体结合,增强其转录.
- FOXM1上调取消了Brusatol对PSAT1的抑制作用,并促进了瘤细胞的存活.
结论:
- FOXM1/PSAT1轴被确定为Brusatol在肺癌中的抗癌活性的关键调解器.
- 布鲁萨托尔通过向FOXM1/PSAT1通路,显示出作为肺癌新型治疗策略的潜力.
- 对这种途径的进一步研究可能会导致改善肺癌治疗方法.
相关概念视频
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
04:43Detection of Lung Tumor Progression in Mice by Ultrasound Imaging
05:11Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities
07:53Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
03:363D Co-culture of Lung Cancer Cells with CAFs: An In Vitro Model System to Study Tumor Progression


